Loading organizations...
Vicept Therapeutics was a biopharmaceutical company developing topical prescription products for dermatological conditions. The firm specialized in creating treatments, such as a topically applied therapy for the erythema of rosacea, addressing chronic skin issues. Its pipeline focused on alleviating skin redness and other related dermatological disorders.
Founded in 2009, Vicept Therapeutics was co-founded by Dr. Neal Walker, then President and CEO, and Stephen Tullman, the Executive Chairman. Their insight centered on the unmet need for effective topically administered treatments for various dermatological conditions, particularly rosacea, leading to the company's formation.
The company aimed to serve patients with chronic dermatological disorders, especially those experiencing skin redness from conditions like rosacea. Vicept Therapeutics' vision was to pioneer and deliver highly effective, topically applied therapies to improve the lives of individuals contending with persistent skin ailments.
Vicept Therapeutics has raised $16.0M across 1 funding round.
Vicept Therapeutics has raised $16.0M in total across 1 funding round.
Vicept Therapeutics has raised $16.0M across 1 funding round. Most recently, it raised $16.0M Series A in June 2010.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2010 | $16M Series A | F Prime Capital, Sofinnova Investments, Vivo Ventures | Frazier Healthcare Partners | Announced |
Vicept Therapeutics has raised $16.0M in total across 1 funding round.
Vicept Therapeutics's investors include F-Prime Capital, Sofinnova Ventures, Vivo Ventures, Frazier Healthcare Partners.
I need to clarify an important point about your query: Vicept Therapeutics is not a technology company—it is a biopharmaceutical company.[1][2] The premise of your question contains an inaccuracy that I should address before proceeding.
Vicept Therapeutics is a specialty biopharmaceutical company focused on developing topically applied therapies for dermatologic disorders.[1] Rather than building software or digital technology products, Vicept develops pharmaceutical treatments designed to be applied directly to the skin. The company is privately held and based in Malvern, Pennsylvania.[3][4]
The company's mission centers on creating effective topical therapeutic solutions for skin conditions—a departure from traditional systemic pharmaceutical approaches. This focus on dermatology represents a specific therapeutic niche within the broader biopharmaceutical sector.
Vicept Therapeutics was founded in August (year not fully specified in available sources).[3][4] The company emerged with a clear strategic focus: to develop the first effective topically applied therapy directed at specific dermatologic conditions.[5] Limited information is available in the search results about the founders' backgrounds or early pivotal moments, which constrains a fuller narrative of the company's origin story.
Vicept operates within the specialty pharmaceutical sector, addressing an underserved segment of dermatologic treatment. The topical delivery approach aligns with broader industry trends toward targeted, localized therapies that may reduce systemic side effects compared to oral or injectable alternatives.
As a privately held biopharmaceutical company, Vicept's trajectory will depend on clinical trial success for its pipeline candidates and eventual regulatory approval pathways. The company's specialized focus on topical dermatologic therapies positions it within a growing market segment, though success will ultimately hinge on clinical efficacy data and commercialization capabilities.
